Gynica is a biotech company driven to improve the lives of hundreds of millions of women worldwide suffering from Endometriosis by providing safe, effective, non-hormonal, intra-vaginal therapeutic solutions through its proprietary IntraVag© technology—a non-invasive, self-administered drug delivery platform. Endometriosis is a chronic and debilitating condition affecting at least 10%—more than 200 million—of women and girls of reproductive age worldwide, severely impacting their quality of life and overall well-being. Characterized by the abnormal growth of endometrial tissue outside the uterus, Endometriosis can cause a range of distressing symptoms, including intense pelvic pain, painful intercourse, menstrual irregularities, and infertility. Increasing awareness, improved diagnostic techniques, and the prevalence of the condition have given rise to the growing demand for safe and effective therapies in an underserved market—with a potential global annual market worth of $180 billion. Gynica is owned by Asana Bio Group, a holding company specializing in life sciences innovations.